The Challenge

Targeting where resistance occurs in the conventional outflow pathway can be hard. Addressing the trabecular meshwork alone, or isolating a single point, may not be enough.

This unique anatomy and the possibility of resistance occurring at any point, means you need a surgical option that addresses all three points.

Between 50-75% of resistance may be in the Trabecular Meshwork1,2,3

Up to 50% of resistance may be in Schlemm’s canal and the distal collector channels1,2,3

The Solution
Only OMNI® targets all three points of resistance.
1

Trabecular meshwork
titratable trabeculotomy

2

Schlemm’s canal
transluminal viscoelastic delivery

3

Collector channels
transluminal viscoelastic delivery

ONE MIGS device

TWO implant free procedures

THREE points of resistance

Learn More
Meet the next generation OMNI® Surgical System.
With OMNI® Surgical System, you can perform two implant-free procedures targeting three points of resistance with one intelligent device.
Two procedures in one
intelligently designed device.
The OMNI® Surgical System is a manually operated device indicated for the delivery of small amounts of viscoelastic fluid during ophthalmic surgery through a custom microcatheter. It is also indicated for the cutting of trabecular meshwork when a trabeculotomy is indicated.
Transluminal Viscoelastic Delivery
With its unique implant-free approach, the OMNI® Surgical System lets you access Schlemm’s canal with the microcatheter through a single clear corneal incision. Intelligently engineered with an internal reservoir delivering a controlled amount of viscoelastic fluid.
Titratable Trabeculotomy
To address the trabecular meshwork as a point of resistance within the conventional outflow pathway, the OMNI® Surgical System lets you perform a titratable trabeculotomy customized to meet your surgical plan.
View live case of the
OMNI® Surgical System
Patient Selection
COMBINED WITH CATARACT SURGERY PATIENT SELECTION
Female, 70 year old:
Blurry vision
  • VA 20/60 OD, 20/40 OS
  • OD: 2-3+ NSC, OS: 1+ NSC
  • History of glaucoma
  • Meds: Travaprost and Cosopt PF, QHS OU
  • IOP: 19 OD, 17 OS
  • Visual field loss
  • CD Ratio: OD 0.5, OS 0.5
STANDALONE PATIENT SELECTION
Male, 72 years old:
Prior cataract surgery
  • VA 20/20 OD, 20/30 OS
  • Previous ocular history of POAG – on Combigan and Lumigan
  • IOP: 21 OD, 23 OS
  • OCT and visual fields reflect Evidence of progression of disease
  • CD Ratio: OD 0.7, OS 0.5
Reimbursement Information
Please download our Reimbursement Guide for OMNI® Surgical System Reimbursement Information
Download

Upcoming Events

August 19, 2020 7:00pm EST
Webinar – Go for Three: The Latest Innovation in MIGS
PART II: HOW DO YOU EDUCATE PATIENTS AND SET EXPECTATIONS?
A Three Part Virtual Symposia Series for Optometrists
August 21-23, 2020
Women in Ophthalmology (WIO)
Virtual
Webinar – Go for Three: The Latest Innovation in MIGS – PART III:
HOW DO YOU MANAGE POST-OP PATIENTS?
A Three Part Virtual Symposia Series for Optometrists
September 9, 2020 7:00pm EST
Kiawah Eye
September 11-13, 2020
Kiawah Island, SC
European Society of Cataract and Refractive Surgeons (ESCRS)
October 2-4, 2020
Virtual
OSN NY
October 16-18, 2020
New York, NY
BMC Vision Summit
October 23-25, 2020
Philadelphia, PA
Interventional Glaucoma Congress (IGC)
October 29-31, 2020
location-svg
Chicago, IL
American Academy of Ophthalmology
November 13-15, 2020
location-svg
Virtual
See Full list See Less list

News

Request more info about the OMNI® Surgical System









Are you a Cataract surgeon?*

Are you MIGS trained?*

Are you a Glaucoma specialist?*

Do you provide post-op care?*